

**Campbell Systematic Reviews**

2009:3

First published: 27 August, 2009

Last revised: 31 October, 2009

# **Effects of Drug Substitution Programs on Offending among Drug-Addicts**

Nicole Egli, Miriam Pina, Pernille Skovbo Christensen, Marcelo Aebi, Martin Killias



**THE CAMPBELL COLLABORATION**

# Colophon

---

|                     |  |
|---------------------|--|
| <b>Title</b>        | Effects of drug substitution programs on offending among drug-addicts                            |
| <b>Institution</b>  | The Campbell Collaboration   |
| <b>Authors</b>      | Egli, Nicole<br>Pina, Miriam<br>Skovbo Christensen, Pernille<br>Aebi, Marcelo<br>Killias, Martin |
| <b>DOI</b>          | 10.4073/csr.2009.3   |
| <b>No. of pages</b> | 39   |
| <b>Last updated</b> | 31 October, 2009   |

---

|                  |  |
|------------------|--|
| <b>Citation</b>  | Egli N, Pina M, Skovbo Christensen P, Aebi MF, Killias M. Effects of drug substitution programs on offending among drug-addicts<br>Campbell Systematic Reviews 2009:3<br>DOI: 10.4073/csr.2009.3   |
| <b>Copyright</b> | © Egli et al.<br>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| <b>Keywords</b>  |  |

---

|  |  |
|--|--|
| <b>Support/Funding</b>                 | This work has been funded by the Swiss Federal Office of Public Health (SFOP). Further support has been received from The Campbell Collaboration as well as from SFI Campbell, The Danish National Centre for Social Research.             |
| <b>Potential Conflicts of Interest</b> | The reviewers have no personal, material, or academic interest whatsoever in the outcome of the review. Financial support by the Swiss Federal Office of Public Health and SFI Campbell does not affect the independence of the reviewers. |

---

|                             |  |
|-----------------------------|--|
| <b>Corresponding author</b> | Martin Killias<br>Institute of Criminology<br>University of Zurich<br>Rämistrasse 74/39<br>CH-8001 Zurich, Switzerland<br>Telephone: +41 44 634 52 51<br>E-mail: martin.killias@rwi.uzh.ch |
|-----------------------------|--|

# Campbell Systematic Reviews

---

**Editors-in-Chief** Mark W. Lipsey, Vanderbilt University, USA  
Arild Bjørndal, Norwegian Knowledge Centre for the Health Services &  
University of Oslo, Norway

## **Editors**

*Crime and Justice* David B. Wilson, George Mason University, USA

*Education* Chad Nye, University of Central Florida, USA  
Ralf Schlosser, Northeastern University, USA

*Social Welfare* Julia Littell, Bryn Mawr College, USA  
Geraldine Macdonald, Queen's University, UK & Cochrane Developmental,  
Psychosocial and Learning Problems Group

**Managing Editor** Karianne Thune Hammerstrøm, The Campbell Collaboration

## **Editorial Board**

*Crime and Justice* David Weisburd, Hebrew University, Israel & George Mason University, USA  
Peter Grabosky, Australian National University, Australia

*Education* Carole Torgerson, University of York, UK

*Social Welfare* Aron Shlonsky, University of Toronto, Canada

*Methods* Therese Pigott, Loyola University, USA  
Peter Tugwell, University of Ottawa, Canada

---

The Campbell Collaboration (C2) was founded on the principle that systematic reviews on the effects of interventions will inform and help improve policy and services. C2 offers editorial and methodological support to review authors throughout the process of producing a systematic review. A number of C2's editors, librarians, methodologists and external peer-reviewers contribute.

The Campbell Collaboration  
P.O. Box 7004 St. Olavs plass  
0130 Oslo, Norway  
[www.campbellcollaboration.org](http://www.campbellcollaboration.org)

---

# Table of Contents

|   |           |
|---|-----------|
| <b>TABLE OF CONTENTS</b>  | <b>3</b>  |
| <b>EXECUTIVE SUMMARY/ABSTRACT</b>                                 | <b>5</b>  |
| Background  | 5         |
| Objectives  | 5         |
| Selection criteria  | 5         |
| Data collection and analysis                                      | 6         |
| Main results  | 6         |
| Conclusion  | 6         |
| <b>1 BACKGROUND OF THE REVIEW</b>                                 | <b>7</b>  |
| <b>2 OBJECTIVES OF THE REVIEW</b>                                 | <b>9</b>  |
| <b>3 METHODS</b>  | <b>10</b> |
| 3.1 Search strategy for identification of relevant studies        | 10        |
| 3.2 Criteria for inclusion and exclusion of studies in the review | 11        |
| 3.3 Types of studies  | 11        |
| 3.4 Types of programs   | 12        |
| 3.5 Types of outcome measures                                     | 13        |
| 3.6 Types of participants   | 13        |
| 3.7 Description of methods used in the component studies          | 14        |
| 3.8 Criteria for determination of independent findings            | 14        |
| 3.9 Details of study coding categories                            | 15        |
| 3.10 Statistical procedures and conventions                       | 15        |
| 3.11 Treatment of qualitative research                            | 15        |
| <b>4 FINDINGS</b>   | <b>16</b> |
| 4.1 Overview  | 16        |
| 4.2 Effects of heroin substitution treatment                      | 16        |
| 4.3 Effects of buprenorphine substitution treatment               | 18        |
| 4.4 Methadone Maintenance Treatment (MMT)                         | 19        |
| 4.5 Effects of naltrexone treatment                               | 24        |
| 4.6 Effects of other substitution treatments                      | 24        |
| <b>5 DISCUSSION</b>   | <b>25</b> |
| <b>6 CONCLUSION</b>   | <b>26</b> |

|           |  |           |
|-----------|--|-----------|
| <b>7</b>  | <b>PLANS FOR UPDATING THE REVIEW</b>                 | <b>27</b> |
| <b>8</b>  | <b>ACKNOWLEDGEMENTS</b>                              | <b>28</b> |
| <b>9</b>  | <b>REFERENCES</b>                                    | <b>29</b> |
| <b>10</b> | <b>STUDIES INCLUDED IN THE SYSTEMATIC REVIEW</b>     | <b>31</b> |
| <b>11</b> | <b>APPENDIX: TABLES OF GENERAL STUDY DESCRIPTORS</b> | <b>36</b> |

---

# Executive Summary/Abstract

---

## BACKGROUND

---

Drug abusers are generally more involved in crime, in particular property crime, than people who are not drug abusers. Substitution programs have been developed in order to improve drug users' quality of life and to decrease their criminal involvement. Several evaluations, but not all, have reported crime reductions following substitution therapies based on heroin and methadone prescription.

---

## OBJECTIVES

---

This systematic review is aimed at gaining an overall picture on the respective effects of prescription of methadone vs. heroin and other substances.

Search strategy: Six databases (Medline, Campbell Crime and Justice Group, National Criminal Justice Reference Service, National Treatment Agency for Substance Misuse, JSTOR and Criminal Justice Abstracts) as well as relevant journals and websites (Harm reduction Journal, Journal of Substance Abuse Treatment, Drug and Alcohol Dependence, Drug and Alcohol Review, Drug and Therapeutics Bulletin, International Journal of Drug Policy, Journal of Clinical Psychopharmacology, *Déviance et Société*, Criminal Justice and Behavior, *Criminologie*, [www.heroinstudie.de](http://www.heroinstudie.de) and [www.drugscope.org.uk](http://www.drugscope.org.uk)) have been searched for relevant studies meeting the inclusion criteria.

---

## SELECTION CRITERIA

---

To be eligible, studies had to assess the effects of any substitution therapy (using e.g. methadone and/or opiates as substitution drugs). Only effects on offending have been considered. Comparisons of competing treatments (substitution therapy vs. any other form of treatment, including placebo treatment or no treatment at all) were restricted to studies meeting level 4 or higher on the scale developed by Sherman et al. (1997). In addition, one-group pre-post evaluations of substitution therapies were included because changes in offending are substantial compared to pre-treatment levels, while comparisons of treatment with several substances often show modest differences. Finally, studies that assessed the impact of drug

substitution at the macro (i.e. city or regional) level were also included. The three different types of studies have been analyzed separately.

---

## **DATA COLLECTION AND ANALYSIS**

---

66 studies were considered, and 46 were selected for inclusion in the review. They separately assess the impact of methadone, buprenorphine, heroin, naltrexone, dihydrocodeine or Levo-alpha-acetylmethadone substitution on the criminal behaviour of opiates addicts. Meta-analytic techniques were used to identify overall effects of several substances. Comparisons of different treatments (i.e. substitution vs. any other treatment) were restricted to studies meeting levels 4 or 5 on the scale developed by Sherman et al. (1997).

---

## **MAIN RESULTS**

---

Heroin maintenance reduces crime significantly more than Methadone maintenance. Methadone maintenance reduces offending more than treatments without substitution therapy, but the mean effect size is not significant ( $p > .1$ ). However, very large (and significant) reductions in criminal behaviour are observed during methadone maintenance therapy with respect to pre-treatment levels. Buprenorphine does not significantly reduce criminal behaviour, although effects are positive, be it with respect to methadone or a placebo. Naltrexone treatment reduces criminality significantly more than behaviour therapy or counselling.

---

## **CONCLUSION**

---

Heroin maintenance has been found to significantly reduce criminal involvement among treated subjects, and it is more effective in crime reduction than methadone maintenance. Methadone maintenance greatly reduces criminal involvement, but apparently not significantly more so than other interventions. Buprenorphine and Naltrexone have been found to be promising, although few studies have been identified using these substances in maintenance treatment.

---

# 1 Background of the Review

For the last decades, drug addiction has become an increasingly worrying problem throughout the Western World. Drug-addicts have been disproportionately involved in criminal activities, making drug-addiction, beyond public health concerns, a formidable challenge to public order. In 8 European countries, burglaries, robberies and other serious crimes increased by several hundred percent between 1970 and 2000 (Killias, 2002, p.115). Comparison of self-reported delinquency in 7 countries (Killias & Ribeaud 1999) suggest that the extent of involvement in property crime among addicts of any kind of hard drugs is about 10 times higher than among non-users. Thus, the increasing trends of robbery and burglary in many Western countries between 1970 and 1995 may reasonably also be seen as a side-effect of increasing drug use.

In response to this phenomenon, numerous programs have been set up to provide drug addicts with narcotics (e.g., heroin prescription programs) and substitution drugs. The intended goals of such treatments have been:

- (1) to improve drug users' quality of life, reducing the risks of overdose or contagious diseases, controlling the quality of drugs available on local markets, preventing marginalization and improving social integration,
- (2) to diminish social costs of drug addiction,
- (3) to reduce drug-related offences and protect public order. It is assumed that drug addicts commit many predatory offences mainly to finance the purchase of drugs, and that criminality will decrease once drugs are supplied to addicts through official channels. The same effect should be observed if drug addicts are supplied with products (such as methadone) that suppress physical effects of withdrawal and, indirectly, the immediate need to consume drugs,
- (4) to reduce public order problems of all sorts. If addicts obtain drugs through official channels, they should spend less time in the search for drugs, which means that they have more time available for legitimate earnings and will less concentrate in places where addicts and dealers regularly gather (e.g., "needle" parks in Switzerland).



Many researchers have studied the effects of drug prescription programs on criminal behaviour among participants. We shall review these programs and try to find out whether they have been effective in reducing criminality.

---

## 2 Objectives of the Review

The review aims at evaluating the effects of drug prescription and substitution programs on criminal behaviour among participants. To be included in this review, studies have to assess the effects of drug substitution on offending. If this review reveals significant effects of such programs on criminality, the results could have implications for crime and justice as well as for drug policies. For example, if the results of our meta-analysis support the conclusion that heroin maintenance reduces criminality, medical prescription of heroin could be an option in the treatment of severely addicted drug users with high criminal involvement whenever reductions in offending is among the priorities.

---

## 3 Methods

---

### 3.1 SEARCH STRATEGY FOR IDENTIFICATION OF RELEVANT STUDIES

---

Relevant studies have been identified through abstracts, bibliographies and databases such as Campbell Crime and Justice Group (C2-SPECTR), National Criminal Justice Reference Service (NCJRS), Medline, Harm Reduction Journal, Journal of Substance Abuse Treatment, National Treatment Agency for Substance Misuse (NHS), National Treatment Outcome Research Study (NTORS), Drug and Alcohol Dependence, Drug and Alcohol Review, Drug and Therapeutics Bulletin from the BMJ group (DTB), International Journal of Drug Policy, Central Committee on the Treatment of Heroin Addicts (CCBA), Journal of Clinical Psychopharmacology, Criminal Justice Abstracts (CJA), *Déviante et Société*, JSTOR, Criminal Justice and Behavior (CJB), Criminologie, the German literature ([Heroinstudie.de](http://Heroinstudie.de)-[www.heroinstudie.de/H-Report P2 engl.pdf](http://www.heroinstudie.de/H-Report P2 engl.pdf)) and [www.drugscope.org.uk](http://www.drugscope.org.uk).

Furthermore, the bibliographies of relevant reviews (Amato *et al.*, 2005; Farrell *et al.*, 1994; Ferri, 2005; Hall, 1998; Holloway, 2005; Kosten *et al.*, 1993; Luty, 2003; Prendergast, 2002) have been consulted.

The keywords that have guided the search for references in databases and bibliographies were the following: drug addiction; drug prescription; substitution programs; controlled trial; re-offending; heroin; methadone; opiates, treatment programs; drug abuse; drug addict, heroin prescription, property crime, cocaine abuse; dexamphetamine; cocaine substitution. In addition, the following combinations of keywords have been used: substitution program + re-offending; heroin + treatment programs; heroin + substitution program; heroin + methadone; opiates + treatment; opiates + substitution; heroin + property crime; substitution programs + property crime, cocaine abuse + dexamphetamine.

Being that the staff of the University of Zurich Institute for Criminology and Criminal Law is multi-lingual, studies published in any of the following languages were eligible for inclusion: English, French, German, Dutch, Italian, Spanish, Portuguese, Romanian, Polish, Ukrainian and Russian. In the protocol, it was foreseen that contacts would be established through international channels, such as

the European Sourcebook Group (with its network of correspondents in more than 40 countries), the European Society of Criminology and the International Society of Criminology, with countries not routinely covered in international reviews of research. No relevant studies were identified through these channels, however. Studies published in any language after 1960 have been considered.

---

### **3.2 CRITERIA FOR INCLUSION AND EXCLUSION OF STUDIES IN THE REVIEW**

---

Randomized studies, quasi-experimental studies and before-after comparisons on the effects on offending of drug substitution programs have been included. Interventions can be court-ordered or unrelated to any involvement of the criminal justice system. Only interventions based on substitution programs (using e.g. methadone and/or opiates as substitution drugs) will be considered. Possible effects beyond offending have not been considered, in particular eventual medical outcomes. A coding protocol was prepared along the guidelines of the Campbell Collaboration. Moreover, our review complies with the current standards of meta-analysis (e.g. as specified in *Practical Meta-Analysis* by Lipsey & Wilson).

---

### **3.3 TYPES OF STUDIES**

---

Studies meeting level 4 or higher on the scale developed by Sherman *et al.* (1997) have been considered for comparing competing treatments. In addition and in order to give the reader the full picture, pre-post studies have been included and mean effect sizes have been computed. Such studies are useful in the present context because changes in offending are often substantial compared to pre-treatment levels, while comparisons of treatment with several substances often show modest differences.

Thus, the following types of studies have been included:

- (1) *One-group, pre/post studies*: studies comparing individual delinquency rates before, during and following treatment. To be eligible, studies had to include the prescription of a drug (e.g., methadone, heroin).
- (2) *Multi-group comparison studies, including both true experimental studies (randomized designs) and quasi-experimental designs*: studies comparing delinquency rates among subjects of an experimental group before, during and following treatment to those of a control group (with or without random assignment). As in the previous paragraph, studies were eligible only if the treatment group underwent substitution therapy. As a control group, we considered any group undergoing an alternative treatment or no treatment at all (including placebo control). For example, if the treatment group was treated with heroin as a substitution drug, the control group could remain untreated or may have received any

other substance as a substitution drug (e.g., methadone). It may also have undergone abstinence therapy with or without psychotherapy, detoxification, etc.

- (3) *Macro level studies*: studies assessing the impact of drug substitution at the macro (*i.e.* city, regional) level. In order to be eligible, such studies needed to measure the impact of the program on delinquency at the city/regional level, using police, court or survey data.

The three different types of studies have been analyzed separately. All of the studies taken into account assess the effects of drug substitution programs on offending.

The inclusion criteria have been restrained with respect to the protocol due to the large number of studies of levels 2 and 3. Whereas pre-post studies have been summarized below (Table 5), studies of level 3 have been dropped since a sufficient number of high-quality group comparisons (levels 4 and 5) have been identified (Tables 1, 2, 3 and 6).

---

## **3.4 TYPES OF PROGRAMS**

---

### **3.4.1 Type of intervention**

Studies reporting effects of drug prescription and drug substitution programs on criminality among drug users have been included. By drug substitution program we understand programs that include the prescription of substances rather than programs based on drug abstinence. Methadone detoxification has not been considered as a substitution program, since the finality is abstinence and doses of methadone are reduced to zero after a relatively short period. The prescription must imply substances considered as substitutes for illegal drugs, for example, methadone or buprenorphine as a substitute of heroin. This excludes the prescription of drugs such as tranquillizers or antibiotics, frequently prescribed to drug users. However, studies using Naltrexone®, an opioid antagonist, have been included as well. The medically assisted prescription of heroin has also been included. This does not mean that heroin is a substitute of heroin, but that the uncontrolled consumption of heroin in the streets is replaced by the prescription of a controlled dosage of heroin, adapted to the user's needs.

Programs that do not include prescription of any substance have not been considered, such as programs based exclusively on, for example, psychotherapy, detoxification, etc, except in control groups where the treatment group underwent a substitution intervention. Only interventions based on substitution therapy (using e.g. methadone and/or opiates as substitution drugs) have been considered.

### **3.4.2 Kinds of drugs to be substituted by programs**

All drugs that are illegal according to international agreements and local (national) laws, such as heroin, morphine, opium, cocaine, crack, ecstasy, amphetamine, LSD, ketamine, cannabis, fentanyl, inhalants etc.

### **3.4.3 Context of programs**

Any program, no matter whether treatment is court-ordered or unrelated to any involvement of the criminal justice system. Programs involving incarcerated drug-addicts have not been considered since re-offending cannot be adequately tested as long as offenders remain in prison. Studies where treatment commences in prison but re-offending is measured after release have been included.

---

## **3.5 TYPES OF OUTCOME MEASURES**

---

The key outcome measure considered is offending as measured by reconviction data, police records and studies on self-reported delinquency. Drug possession and consumption has not been considered expressly as a measure of offending although it is an offence in most countries. Since in many studies the overall number of crimes (as measured by self reports, arrests, convictions or incarcerations) is reported, drug possession and consumption is certainly included in some of these general outcome measures. To the extent that studies address the effects at the macro level, any conventional outcome measures (statistics, crime victim surveys etc.) have been considered.

To assess improvement at the individual level, prevalence rates (or percentage of people who re-offend) as well as incidence rates (or number of offences committed per person) during standardized pre- and post-intervention periods have been considered. Prevalence rates inform on *how many persons* are diverted from criminal activity by prescription of substitution products, whereas incidence rates allow assessing whether *fewer offences* are committed as a result of the program. It is important to make this distinction since a given program may reduce the number of offences without affecting the number of offenders.

Possible treatment effects beyond offending, such as medical outcomes or effects of such programs on drug markets have not been considered.

---

## **3.6 TYPES OF PARTICIPANTS**

---

The considered population consists of drug-addicts (*e.g.* heroin addicts, cocaine addicts), adults and adolescents, males and females.

---

### **3.7 DESCRIPTION OF METHODS USED IN THE COMPONENT STUDIES**

---

The methods used by the studies covered by this review can be the following ones: Randomized studies, quasi-experimental studies and before-after comparisons.

All studies included in this review will have a measure of the effects of drug substitution treatments on offending such as arrest, conviction, incarceration or self-reports.

---

### **3.8 CRITERIA FOR DETERMINATION OF INDEPENDENT FINDINGS**

---

There are three potential sources of non-independence of findings. We shall use the same criteria as in similar Campbell Review Protocols (*e.g.* Lipsey and Landenberger (2006); Wilson *et al.*(2007)).

The first potential source of non-independence of findings is multiple indicators of offending reported from a single study (*e.g.* arrest, conviction). When more than one such outcome is reported, only one will be selected for the analysis. To maintain as much comparability as possible across studies, coders have selected the outcome measure that is most frequently represented in other studies in the collection (Lipsey *et al.*, 2006). This has been “all offences”, measured usually at the level of arrests or self-reports. If “all offences” was not available, any among several outcomes was selected randomly.

The second occurs when the same outcome is measured at multiple points in time, *e.g.*, 6-months, 12-months, 18-months and two years post-treatment. In those cases, the measure with the timing closest to that most commonly used across all the studies (12 months) has been chosen to maximize comparability between studies (Lipsey *et al.*, 2006).

Finally, the third source of non-independent findings is the same data being reported across multiple documents. We have used author’s names, court location and study time frames as well as sample descriptions to identify multiple publications of the same evaluation. When such multiple publications were identified, the most complete and detailed manuscript was designated as the primary coding source. Additional manuscripts have been consulted to elaborate coding if necessary (Wilson *et al.*, 2007).

---

### **3.9 DETAILS OF STUDY CODING CATEGORIES**

---

A coding protocol was developed for this synthesis that provides for a systematic method of extracting information regarding each study's research design, program, nature of the outcome measure, and outcome data (see appendix- Coding Protocol).

---

### **3.10 STATISTICAL PROCEDURES AND CONVENTIONS**

---

Our review complies with the current standards of meta-analysis (*e.g.* as specified in *Practical Meta-Analysis* by Lipsey & Wilson).

The three types of studies mentioned above (pre/post studies, randomized controlled trials and quasi-experimental designs, and macro-level studies) have been synthesized and meta-analyzed separately.

The effect of drug prescription or substitution programs on criminal behaviour was encoded using the odds-ratio. The odds-ratio is well suited to dichotomous outcomes, such as those commonly used in drug treatment. When offending was measured (quasi-) continuously (crime days, number of arrests), a standardized mean difference type effect size was computed and transformed into an odds-ratio (see Lipsey & Wilson, 2001). For pre-post studies, odds ratios have been computed between  $t_0$  and  $t_1$ . An odds ratio of  $>1.0$  indicates that treatment reduced offending, and an odds ratio of  $<1.0$  was used whenever treatment was unsuccessful. Effect size outliers ( $>\pm 3.0$  standard deviations) would have been winsorized to less extreme values (next highest not judged an outlier); however, no such outliers were observed. In addition, no data were imputed for missing values.

For the computation of mean-effect sizes, the inverse variance method of meta-analysis (Lipsey & Wilson, 2001) was used. In the first place, fixed-effect models were fitted. Whenever the Q-test refuted homogeneity, a random effects model was adopted.

---

### **3.11 TREATMENT OF QUALITATIVE RESEARCH**

---

No qualitative research was included in this systematic review.



---

## 4 Findings

---

### 4.1 OVERVIEW

---

In Medline, 3,791 studies have been found using the searches with combined keywords. All different searching strategies together yielded 459 references to be retained for further examination; 68 are reviews, 220 have been rejected as being out of the scope of the present review (of these, 168 are available as full text versions), and 171 have been retained as being of interest (of these, 152 are available as full text). Among the 171 references retained, there are cases where several articles refer to a same study, while not necessarily reporting the same results. Sixty-six studies have been coded. 46 of these either fulfil criteria of Sherman 4 or higher or are pre-post comparisons or population studies and have therefore been included in the present review.

---

### 4.2 EFFECTS OF HEROIN SUBSTITUTION TREATMENT

---

Among the coded eligible studies, 6 concern Heroin substitution programs, and 5 are randomized controlled trials (RCTs). In four of the RCTs, the control group undergoes methadone maintenance (Dijkgraaf, 2005; Hartnoll *et al.*, 1980; Löbmann *et al.*, 2008; March *et al.*, 2006), while in one (Perneger, 1998) the control group undergoes any conventional treatment (mostly Methadone maintenance treatment, MMT). A general description of these studies is available in the appendix, Table A1. One study is an intake-follow up investigation of the efficacy of Heroin (Killias *et al.*, 1999). It was excluded from the models shown below. The effect sizes retained for these studies as well as the Random- and Fixed effects model effect sizes are reported in Table 1 below.

Table 1: Studies where treatment group receives Heroin maintenance and the control group either methadone or another standard treatment.


| First author   | Year | Outcome                  | OR    | CI low | CI high | p       |
|----------------|------|--------------------------|-------|--------|---------|---------|
| Dijkgraaf      | 2005 | Arrest / property crime  | 1.33  | 0.94   | 1.88    | 0.11    |
| Perneger       | 1998 | Charged/any offense      | 33.52 | 5.52   | 203.6   | 0.0001  |
| Hartnoll       | 1980 | Arrest/any offense       | 2.37  | 1.08   | 5.22    | 0.03    |
| March          | 2006 | Commission / any offense | 3.64  | 1.29   | 10.31   | 0.015   |
| Löbmann        | 2008 | Charged / theft          | 1.43  | 0.79   | 2.59    | 0.24    |
| Fixed effects  |      |                          | 1.65  | 1.27   | 2.16    | 0.0002  |
| Random effects |      |                          | 2.44  | 1.27   | 4.69    | 0.0072  |
| Killias        | 1999 | Conviction / any offense | 6.58  | 4.46   | 9.69    | <0.0001 |

Notes: (1) The first five studies are RCTs and have been included in the model, while the last one is a pre-post study and that was excluded from the model.

(2) An odds ratio >1.0 stands for a reduction in offending after treatment.

(3) p is based on z-tests.

Figure 1: Forest plot<sup>1</sup> for the comparison described in table 1. The size of the boxes is proportional to the weight of the study in the summary measures. The confidence interval for the study by Perneger et al (2008) has been cut for representation (arrow).



The standard deviation for all effects is 14.04; none of the studies was therefore winsorized. However, the study by Perneger (1998) includes 21 subjects in control group, and 27 in the treatment group; also, the confidence interval for this odds ratio is [5.52;203.6] and therefore, effects observed are very variable, certainly due to (1) the heterogeneous control group and (2) a small sample size. The Killias et al.

<sup>1</sup> Forest plots have been constructed using R ([www.r-project.org](http://www.r-project.org)).

(1999) study may have a higher effect size because subjects in the Swiss heroin trial were selected for treatment considering particularly their high criminal involvement.

The hypothesis of homogeneity is here rejected. If Perneger (1998) is not included in the analysis, due to the different treatment of the control group with respect to all other included studies, homogeneity is accepted. The Fixed effects mean effect size is then 1.55 [1.18; 2.02] ( $p=0.0015$ ). Here, a significant decrease in the criminality measures is, therefore, present for Heroin rather than Methadone maintenance.

---

### 4.3 EFFECTS OF BUPRENORPHINE SUBSTITUTION TREATMENT


---

For the effect of Buprenorphine on criminal behaviour, 4 studies have been found. 3 of these are RCTs. In two, the control group is in MMT (Harris *et al.*, 2005; Magura *et al.*, 2008, while in the third (Krook, 2002), the control group receives a placebo only. The individual and overall effects are shown in Table 2 below, while general descriptors of the studies are presented in the Appendix (Table A2). The fourth study (Kakko *et al.*, 2003) is a randomized controlled trial as well, but the measure of criminality is only given for the treatment group in pre-post form.

*Table 2: Studies where treatment group receives Buprenorphine maintenance. The first 3 are RCTs, while in the last the crime measure is only given in a pre-post form.*

| First author   | Year | Outcome                     | OR   | CI low | CI high | p       |
|----------------|------|-----------------------------|------|--------|---------|---------|
| Harris         | 2005 | Cost of crime / any offense | 5.74 | 3.03   | 10.86   | <0.0001 |
| Krook          | 2002 | Commission / any offense    | 3.88 | 0.92   | 16.40   | 0.07    |
| Magura         | 2008 | Arrest / any offense        | 1.01 | 0.46   | 2.22    | 0.99    |
| Fixed effects  |      |                             | 2.98 | 1.86   | 4.77    | <0.0001 |
| Random effects |      |                             | 2.78 | 0.81   | 9.53    | 0.10    |
| Kakko          | 2003 | Commission / any offense    | 2.41 | 0.77   | 7.53    | 0.13    |

Figure 2: Forest plot for the comparison described in table 2. The size of the boxes is proportional to the weight of the study in the summary measures.



The hypothesis of homogeneity is refuted (Q test  $p=0.0033$ ), and when the study with a differing control group (Krook et al., 2002) is excluded, this remains so (Q test  $p=0.0008$ ). Overall, there is therefore no significant reduction in criminality when Buprenorphine instead of Methadone is used, although the effects have a tendency to be positive with Buprenorphine with respect to Methadone (or Placebo).

---

#### 4.4 METHADONE MAINTENANCE TREATMENT (MMT)


---

For methadone maintenance, 41 studies have been found and coded; 2 of these are population studies, 11 are quasi-experimental studies (but 8 are Sherman 2 or 3 and have therefore been excluded, since a large number of studies have been found), 21 are pre-post studies and 7 RCTs. The included studies are 7 RCTs and 3 quasi-experimental studies. Among the RCTs, the control groups differ widely: three are waiting-list controls (Dole *et al.*, 1969; Schwartz *et al.*, 2007; Yancovitz *et al.*, 1991), in one the control group receives a placebo (R. Newman *et al.*, 1979), in one the control group receives counselling (Kinlock, 2008), in one the control group receives detoxification (Sees *et al.*, 2000), and in one the control is treatment community (Bale *et al.*, 1980). Among the quasi experimental studies, two controls are detoxification (Daley, 2000; Haglund *et al.*, 1978) and one residential treatment (Teesson, 2006). A general description of these studies is given in the Appendix, Table A3.

Table 3: Studies fulfilling criteria of Sherman 4 or 5 where treatment group receives Methadone maintenance vs. control group with no substitution treatment.

| First author   | Year | Outcome                      | OR   | CI low | CI high | p     |
|----------------|------|------------------------------|------|--------|---------|-------|
| Daley          | 2000 | Cost of crime / any offence  | 0.83 | 0.29   | 2.34    | 0.72  |
| Teesson        | 2006 | Commission / any offence     | 1.16 | 0.60   | 2.24    | 0.65  |
| Haglund        | 1987 | Arrest / any offence         | 0.39 | 0.12   | 1.29    | 0.12  |
| Kinlock        | 2008 | Incarceration / any offence  | 2.73 | 1.12   | 6.67    | .003  |
| Dole           | 1969 | Incarceration / any offence  | 45   | 4.04   | 500.71  | 0.002 |
| Bale           | 1980 | Arrest / any offence         | 0.88 | 0.48   | 1.61    | 0.68  |
| Newman         | 1979 | Conviction / any offence     | 2.29 | 0.97   | 5.4     | 0.06  |
| Schwartz       | 2007 | Illegal income / any offence | 1.18 | 0.78   | 1.77    | 0.44  |
| Yankowitz      | 1991 | Incarceration/ any offence   | 0.49 | 0.04   | 5.43    | 0.56  |
| Sees           | 2000 | ASI legal / any offence      | 2.47 | 1.31   | 4.63    | 0.01  |
| Fixed effects  |      |                              | 1.34 | 1.06   | 1.70    | 0.01  |
| Random effects |      |                              | 1.40 | 0.91   | 2.16    | 0.12  |

Figure 3: Forest plot for the comparison described in table 3. The size of the boxes is proportional to the weight of the study in the summary measures. The confidence intervals of Dole (1969) and Yankovitz (1991) are cut for the representation (arrows).



Again, homogeneity analysis refutes the hypothesis of homogeneity ( $p=0.0047$ ). The random effects model does not indicate a significant effect of methadone maintenance with respect to these control groups; the mean effect measure is, however, in favour of Methadone maintenance.


When groups are analysed separately by control groups, the between group variability is not significant. Also, homogeneity is not rejected for the detoxification ( $p=0.35$ ) and counselling/residential treatment / treatment community (TC) control groups ( $p=0.63$ ). Detailed results are given in table 4.

Table 4: Effects on criminal behaviour for Methadone maintenance by type of treatment offered to the control group. Studies included fulfil Sherman 4 or 5.

| Control                             | Nb of studies | Mean ES | CI ES low | CI ES high | p    |
|-------------------------------------|---------------|---------|-----------|------------|------|
| Detoxification <sup>a</sup>         | 3             | 1.41    | 0.86      | 2.31       | 0.17 |
| Waiting list <sup>b</sup>           | 3             | 2.58    | 0.29      | 22.8       | 0.39 |
| Resid. / TC / Counsel. <sup>a</sup> | 3             | 1.22    | 0.82      | 1.82       | 0.32 |
| Placebo <sup>a</sup>                | 1             | 2.29    | 0.97      | 5.4        | 0.06 |

Effect sizes indicated are based on a <sup>a</sup> fixed effects model and <sup>b</sup> a random effects model. P is based on z-tests.

Figure 4: Forest plot for the comparison described in table 4. The size of the boxes is proportional to the inverse variance of the odds ratio in every group of studies.



Therefore, Methadone maintenance has no significantly better effect on criminality than any of these control treatments. Also, a non-significant but positive effect of Methadone maintenance over all other control conditions is detected.


In table 5, the results for the pre-post (or rather, during) studies using methadone are reported. One of these studies is a randomized controlled trial of oral versus intravenous methadone delivery (Strang *et al.*, 2000); only the pre-post results of the oral methadone group are presented here, since it was decided to compare different substances of substitution rather than dosages or ways of administration. Effect sizes (log odds ratios) have been computed by comparing pre-treatment levels of offending and average individual offending rates during maintenance treatment. This explains the sometimes very large odds ratios obtained. Also, the maximum effect size obtained (1081) is observed in a study with only 24 participants.

Table 5: Pre-post studies of Methadone maintenance

| First author        | Year | Outcome                                   | OR     | CI low | CI high | p       |
|---------------------|------|---|--------|--------|---------|---------|
| Rothbard            | 1999 | Arrest /Any offence                       | 0.74   | 0.62   | 0.89    | 0.0017  |
| Déglon              | 1994 | Days incarcerated / any offence           | 11.17  | 4.05   | 30.80   | <0.0001 |
| Cushman             | 1974 | Arrest / property offence                 | 8.18   | 3.36   | 19.92   | <0.0001 |
| Dole                | 1968 | Conviction / any offence                  | 170.44 | 118.67 | 244.82  | <0.0001 |
| Bali                | 1988 | Commission / any offence                  | 26.68  | 18.72  | 38      | <0.0001 |
| Schut               | 1975 | Arrest / violent offence                  | 14.79  | 4.81   | 45.43   | <0.0001 |
| Grella <sup>a</sup> | 1995 | Commission / theft                        | 0.69   | 0.32   | 1.49    | 0.34    |
| Grella <sup>b</sup> | 1995 | Commission / theft                        | 1.69   | 0.98   | 2.92    | 0.06    |
| Grella <sup>c</sup> | 1995 | Commission / theft                        | 0.85   | 0.38   | 1.87    | 0.68    |
| Cushman             | 1976 | Arrest / any offence                      | 8.63   | 5.72   | 13.01   | <0.0001 |
| Newman              | 1973 | Arrest / any offence                      | 6.14   | 3.94   | 9.57    | <0.0001 |
| Langrod             | 1973 | Arrest / any offence                      | 26.8   | 17.72  | 40.64   | <0.0001 |
| Keen                | 2000 | Conviction and caution / any offence      | 1.67   | 0.86   | 3.27    | 0.13    |
| Keen                | 2003 | Commission / property crime               | 18.25  | 5.41   | 61.64   | <0.0001 |
| Walger              | 1989 | Incarceration / any offence               | 1081   | 33.34  | 35041   | <0.0001 |
| Strang              | 2000 | Commission / property offences            | 1.57   | 0.31   | 7.85    | 0.55    |
| Simpson             | 1997 | Commission or incarceration / any offence | 5.02   | 2.81   | 8.96    | <0.0001 |
| Sheerin             | 2004 | Commission / any offence                  | 148.50 | 18.56  | 1188    | <0.0001 |
| Perreault           | 2007 | Earning from illegal activity             | 2.53   | 1.02   | 6.27    | 0.04    |
| Kott                | 2001 | Arrest / any offence                      | 4.44   | 1.58   | 12.48   | 0.0047  |
| Bates               | 1996 | Conviction / any offence                  | 2.56   | 0.91   | 7.17    | 0.07    |
| Fixed effects       |      |   | 4.37   | 3.94   | 4.86    | <0.0001 |
| Random effects      |      |   | 6.92   | 3.04   | 15.77   | <0.0001 |

<sup>a</sup> Results for white <sup>b</sup> for African-American and <sup>c</sup> for Latino women

Figure 5: Forest plot for the comparison described in table 5. The size of the boxes is proportional to the weight of the study in the summary measures. The confidence intervals for Walger (1989) and Sheerin (2004) have been cut for representation (arrows).



The hypothesis of homogeneity is again rejected. Here, a beneficial effect of methadone maintenance is observed with respect to baseline. This in no way contradicts results obtained above, where Methadone is not significantly more effective than other substances in reducing criminality; indeed, these pre-post studies only show decreasing criminality during treatment, not whether this is a comparatively effective treatment or even whether the effect is due to being in treatment or to the passage of time.

As for the two population studies, only general results will be reported here since none includes comparison macro units. The first one, carried out by Niveau *et al* (2002) reports a significant positive correlation of crime known to the police in Geneva with the number of addicts in MMT (with  $r$  of 0.71 [0.73; 0.68]). In a reaction, however, Aebi (2001) observed that the overall population of drug addicts needs to be taken into account in such a trend analysis. When this is done, the effect turns in favour of MMT with a significant  $r$  of -0.19 [-0.14; -0.24]. In the second population study (Maddux & Desmond, 1979), a negative correlation is obtained, with an  $r$  of -0.93 [-1.03, -0.84].




## 4.5 EFFECTS OF NALTREXONE TREATMENT

While Naltrexone is not a substitution treatment (rather the prescription of an inhibiting substance) it is included; effects are shown in table 6. Two RCTs have been found, one contrasting Naltrexone with counselling (Cornish et al., 1997) and one with behaviour therapy (Rawson, 1979); also, one pre-post trial is shown in table 6 (De Jong *et al.*, 2007). The descriptors of the studies included in the meta-analysis are given in the Appendix, Table A4.

Table 6: Effects of Naltrexone on criminal behaviour

| First author   | Year | Outcome  | OR   | CI low | CI high | p       |
|----------------|------|--|------|--------|---------|---------|
| Cornish        | 1997 | Incarceration / any offense ( + probation violation) | 3.61 | 1.06   | 12.35   | 0.04    |
| Rawson         | 1979 | Incarceration / any offense                          | 1.66 | 1.39   | 1.99    | <0.0001 |
| Fixed effects  |      |  | 3.21 | 1.23   | 8.31    | 0.02    |
| Random effects |      |  | 3.21 | 1.23   | 8.31    | 0.02    |
| De Jong        | 2007 | EuropASI justice / police                            | 2.67 | 0.59   | 12.09   | 0.20    |

Figure 6: Forest plot for the comparison described in table 6. The size of the boxes is proportional to the weight of the study in the summary measures.



Here, homogeneity is not rejected by the test; Naltrexone is here shown to have a significant and beneficial effect on criminal behaviour with respect to psychological interventions.

## 4.6 EFFECTS OF OTHER SUBSTITUTION TREATMENTS

Finally, two RCTs have been found that use other replacement therapies: one where Levo-alpha-acetylmethadone (LAAM) is compared to MMT (Eissenberg et al., 1997) and one where MMT is compared to Dihydrocodeine (Robertson et al., 2006). In the first case, the effect favours LAAM; the effect size is 1.93 [0.16, 22.31] and the effect is not significant. However, very serious side-effects (torsade de pointes) have been observed with this substitution drug that is, for this reason, unavailable in Europe. In the second case, the effect size is 0.96 [0.39; 2.37] and is not significant either.

---

## 5 Discussion

Two systematic reviews of substitution programs have been carried out to be included in the Cochrane database of systematic reviews: Ferri *et al* (2006) and Mattick *et al* (2006). While these reviews do not focus on delinquency as an outcome measure, a comparison of results with the present report seems relevant. In Ferri *et al* (2006), 4 trials comparing methadone maintenance to Heroin maintenance are included. One study showed a reduction in the risk of being charged when on Heroin maintenance; this in line with the results obtained here. Also, two studies considered criminal offending and social functioning in a multi domain outcome measure, and again, heroin plus methadone maintenance yields better results than methadone alone. Again, this is in line with the results obtained here, i.e. heroin maintenance reduced criminality more than other maintenance treatments.

In Mattick *et al* (2006), three studies comparing methadone maintenance to no opioid replacement therapy with respect to their effect on criminal behaviour are included. The results obtained are similar to the results obtained here in two respects: firstly, the effect of methadone maintenance seems to reduce criminal behaviour more than the alternatives, and secondly, this effect is not significant.

---

## 6 Conclusion

Heroin maintenance reduces crime significantly more than Methadone maintenance. Methadone maintenance itself does not have a significant effect on criminal behaviour; in particular with respect to two detoxification and one treatment community program, the effect is even negative. While Methadone maintenance is, with respect to reductions in offending, not to be the preferred treatment, it was found to be promising in comparison to detoxification, treatment community, counselling and residential treatment, placebo and waiting list controls. These reductions are not significant, while very large (and significant) reductions in criminal behaviour are observed during Methadone maintenance with respect to pre-treatment levels.

Buprenorphine does not significantly reduce criminal behaviour, although effects are strictly positive, be it with respect to Methadone or a placebo.

Finally, a quite different treatment has been evaluated here as well: Naltrexone. This treatment reduces criminality significantly more than behaviour therapy or counselling.

Overall, crime reduction among addicts, though important in itself, will probably not be the only goal to give attention to. This review does not address other (possibly different) effects of substitution therapy on other goals, such as promoting abstinence or improving health.

---

## 7 Plans for updating the Review

This review will be updated every five years to include new treatment studies published in any language. The primary authors will take the lead in this update.

---

## 8 Acknowledgements

We would like to thank the Swiss Federal Office of Public Health (SFOP), the Campbell Collaboration as well as SFI Campbell, for the support given to this project.

---

## 9 References

Amato, L., Davoli, M., C, A. P., Ferri, M., Faggiano, F., & R, M. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. *Journal of Substance Abuse Treatment*, 28(4), 321-329.

Farrell, M., Ward, J., Mattick, R., Hall, W., Stimson, G. V., des Jarlais, D., et al. (1994). Methadone maintenance treatment in opiate dependence: a review.[see comment]. *BMJ*, 309(6960), 997-1001.

Ferri, M., Davoli, M., & Perucci, C. A. (2005). Heroin maintenance for chronic heroin dependents (Review). *Cochrane Database of Systematic Reviews*, 1-16.

Hall, W. (1998). Methadone maintenance treatment as a crime control measure. *Crime and justice Bulletin*(29), 1-12.

Holloway, K., Bennett, T. & Farrington, D. (2005). *The effectiveness of criminal justice and treatment programmes in reducing drug related crime: a systematic review*. UK: Research Development and Statistics Directorate, Home Office.

Killias, M. (2002). *Grundriss der Kriminologie- Eine europäische Perspektive*. Berne: Stämpfli.

Killias, M., & Ribeaud, D. (1999). Drug use and crime among juveniles: An international perspective. *Studies on crime and crime prevention*, 8(2), 189-209.

Kosten, T. R., Schottenfeld, R., Ziedonis, D., & Falcioni, J. (1993). Buprenorphine versus methadone maintenance for opioid dependence. *Journal of Nervous and Mental Disease*, 181(6), 358-364.

Lipsey, M. W., & Landenberger, N. A. (2006). Cognitive-Behavioral Programs for juvenile and adult offenders: A meta-analysis of controlled intervention studies. From [http://db.c2admin.org/doc-pdf/CBT\\_Meta\\_Protocol\\_revised.pdf](http://db.c2admin.org/doc-pdf/CBT_Meta_Protocol_revised.pdf); last consulted : 3.10.2008

Lipsey, M. W., & Wilson, D. B. (2001). *Practical meta-analysis*. Thousand Oaks, CA Sage.

Luty, J. (2003). What works in drug addiction? *Advances in Psychiatric Treatment*, 9, 280-288.

Mattick RP., Breen, C., Kimber, J., & Davoli, M. (2006). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Cochrane Review). In *The Cochrane Database of Systematic Reviews* , 3, 1-19. UK: John Wiley & Sons, Ltd.

Prendergast, M., Podus, D., Chang, E. & Urada, D. (2002). The effectiveness of drug abuse treatment: a meta-analysis of comparison group studies. *Drug and Alcohol Dependence*, 67(1), 53-72.

Sherman, L. W., Gottfredson, D., Mackenzie, D., Eck, J., Reuter, P., & Bushway, S. (1997). What works, what doesn't, what's promising? A report to the United States Congress: University of Maryland: Department of Criminology and Criminal Justice.

Wilson, D. B., Mitchell, O., & Mackenzie, D. L. (2007). Effects of drug courts on criminal offending and drug use: A Campbell Collaboration Systematic Review Protocol. From [http://db.c2admin.org/doc-pdf/dcprotocol\\_v4.pdf](http://db.c2admin.org/doc-pdf/dcprotocol_v4.pdf); last consulted : 2.10.2008.

---

## 10 Studies Included in the Systematic Review

Aebi, M. F. (2001). La relation entre cures de substitution à la méthadone et prévention de la délinquance : une réponse critique à Niveau et Laureau. *Déviance et Société*, 25, 187-203.

Bale, R. N., Van Stone, W. W., Kuldau, J. M., Engelsing, T. M., Elashoff, R. M., & Zarcone, V. P. J. (1980). Therapeutic communities vs methadone maintenance: A prospective controlled study of narcotic addiction treatment: Design and one-year follow-up. *Archives of General Psychiatry*, 37(2), 179-193.

Bali, J., Corty, E., Bond, H., Myers, C., & Tommasello, A. (1988). The reduction of intravenous heroin use, non-opiate abuse and crime during methadone maintenance treatment: further findings. *NIDA Research Monograph*, 81, 224-230.

Bates, M., & Pemberton, D. A. (1996). The effect of methadone prescribing in a clinic setting on the criminal activity of drug users. *Scottish Medical Journal*, 41(6), 173-175.

Cornish, J. W., Metzger, D., Woody, G. E., Wilson, D., McLellan, A. T., Vandergrift, B., et al. (1997). Naltrexone pharmacotherapy for opioid dependent federal probationers. *Journal of Substance Abuse Treatment*, 14(6), 529-534.

Cushman, P. (1974). Narcotic addiction and crime. *RI Medical Journal*, 57(5), 197-204 passim.

Cushman, P., Trussell, R., Gollance, H., Newman, R., & Bihari, B. (1976). Methadone maintenance treatment of narcotic addiction: a unit of medical care based on over 50,000 patient treatment years. *American Journal of Drug & Alcohol Abuse*, 3(2), 221-233.

Daley, M., Argeriou, M., McCarty, D., Callahan Jr<sup>a</sup>, Shepard, D. S. & Williams, C. N. (2000). The costs of crime and the benefits of substance abuse treatment for pregnant women. *Journal of Substance Abuse Treatment*, 19(4), 445-458.



- De Jong, C. A., Roozen, H. G., van Rossum, L. G., Krabbe, P. F., & Kerkhof, A. J. (2007). High abstinence rates in heroin addicts by a new comprehensive treatment approach. *American Journal on Addictions*, *16*(2), 124-130.
- Déglon, J. J. (1994). [How do the substitution programs help in social integration of drug addicts?]. *Annales de Medecine Interne*, *145 Suppl 3*, 100-101.
- Dijkgraaf, M., van der Zanden, B., Borgie, C., Blanken, P., van Ree, J. & van den Brink, W. (2005). Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomized trials. *British Medical Journal*, *330*(7503), 1-6.
- Dole, V. P., Nyswander, M. E., & Warner, A. (1968). Successful treatment of 750 criminal addicts. *JAMA*, *206*(12), 2708-2711.
- Dole, V. P., Robinson, J. W., Orraca, J., Towns, E., Searcy, P., & Caine, E. (1969). Methadone treatment of randomly selected criminal addicts. *New England Journal of Medicine*, *280*(25), 1372-1375.
- Eissenberg, T., Bigelow, G. E., Strain, E. C., Walsh, S. L., Brooner, R. K., Stitzer, M. L., et al. (1997). Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial. *JAMA*, *277*(24), 1945-1951.
- Grella, C. E., Annon, J. J., & Anglin, M. D. (1995). Ethnic differences in HIV risk behaviors, self-perceptions, and treatment outcomes among women in methadone maintenance treatment. *Journal of Psychoactive Drugs*, *27*(4), 421-433.
- Haglund, R. M., & Froland, C. (1978). Relationship between addict crime and drug treatment: two cohorts examined. *American Journal of Drug & Alcohol Abuse*, *5*(4), 455-462.
- Harris, A. H., Gospodarevskaya, E., & Ritter, A. J. (2005). A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. *Pharmacoeconomics*, *23*(1), 77-91.
- Hartnoll, R. L., Mitcheson, M. C., Battersby, A., Brown, G., Ellis, M., Fleming, P., et al. (1980). Evaluation of heroin maintenance in controlled trial. *Archives of General Psychiatry*, *37*(8), 877-884.
- Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003). 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet*, *361*(9358), 662-668.

Keen, J., Oliver, P., Rowse, G., & Mathers, N. (2003). Does methadone maintenance treatment based on the new national guidelines work in a primary care setting?[see comment]. *British Journal of General Practice*, 53(491), 461-467.

Keen, J., Rowse, G., Mathers, N., Campbell, M., & Seivewright, N. (2000). Can methadone maintenance for heroin-dependent patients retained in general practice reduce criminal conviction rates and time spent in prison? *British Journal of General Practice*, 50(450), 48-49.

Killias, M., Aebi, M. F., Ribeaud, D. & Rabasa, J. (1999). Rapport final sur les effets de la prescription de stupéfiants sur la délinquance des toxicomanes. 2ème édition élargie. Université de Lausanne.

Kinlock, T., Gordon, M., Schwartz, R. & O'Grady, K. (2008). A Study of Methadone Maintenance for Male Prisoners: 3-Month Postrelease Outcomes. *Criminal Justice and Behavior*, 35(1), 34-47.

Kott, A., Habel, E., & Nottingham, W. (2001). Analysis of behavioral patterns in five cohorts of patients retained in methadone maintenance programs. *Mount Sinai Journal of Medicine*, 68(1), 46-54.

Krook, A. L., Brors, O., Dahlberg, J., Grouff, K., Magnus, P., Roysamb, E., et al. (2002). A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. *Addiction*, 97(5), 533-542.

Langrod, J., Warner, A., Bitz, K., & Jarvis, N. (1973). Rehabilitation of lower and middle class heroin addicts: a comparison of patients in public and private methadone maintenance treatment. *Proceedings - National Conference on Methadone Treatment*, 1, 728-732.

Löbmann, R., Köllisch, T., & Kreuzer, A. (2008). *Das bundesdeutsche Modellprojekt zur heroingestützten Behandlung Opiatabhängiger Band 2 – Der Einfluss der Diamorphinbehandlung auf Kriminalität und Delinquenz Opiatabhängiger*. Baden-Baden: Nomos.

Maddux, J. F., & Desmond, D. P. (1979). Crime and treatment of heroin users. *International Journal of the Addictions*, 14(7), 891-904.

Magura, S., Lee, J. D., Hershberger, J., Joseph, H., Marsch, L., Shropshire, C., et al. (2008). Buprenorphine and Methadone Maintenance in Jail and Post-Release: A Randomized Clinical Trial. *Drug & Alcohol Dependence*, In press.

- March, J. C., Oviedo-Joekes, E., Perea-Milla, E., Carrasco, F., & team, P. (2006). Controlled trial of prescribed heroin in the treatment of opioid addiction. *Journal of Substance Abuse Treatment*, *31*(2), 203-211.
- Newman, R., & Whitehill, W. (1979). Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. *The Lancet*, *314*(8141), 485-488.
- Newman, R. G., Bashkow, S., & Cates, M. (1973). Arrest histories before and after admission to a methadone maintenance treatment program. *Proceedings - National Conference on Methadone Treatment*, *1*, 109-115.
- Niveau, G., Rougemont, A. L., La Harpe, R. (2002). Methadone maintenance treatment, criminality and overdose-related deaths. An ecological study, 1983-1999. *European Journal of Public Health*, *12*(3), 224-227.
- Perneger, T., Giner, F., Del Rio, M. & Mino, A. (1998). Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. *British Medical Journal*, *317*(7150), 13-18.
- Perreault, M., Heroux, M. C., White, N. D., Lauzon, P., Mercier, C., & Rousseau, M. (2007). [Treatment retention and evolution of clientele in a low threshold methadone substitution treatment program in Montreal]. *Canadian Journal of Public Health Revue Canadienne de Sante Publique*, *98*(1), 33-36.
- Rawson, R. A., Glazer, M., Callahan, E.J., Liberman, R.P. (1979). Naltrexone and behaviour therapy for heroin addiction. . *NIDA Research Monograph Series*, *25*, 26-43.
- Robertson, J. R., Raab, G. M., Bruce, M., McKenzie, J. S., Storkey, H. R., & Salter, A. (2006). Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial.[see comment]. *Addiction*, *101*(12), 1752-1759.
- Rothbard, A., Alterman, A., Rutherford, M., Liu, F., Zelinski, S., & McKay, J. (1999). Revisiting the effectiveness of methadone treatment on crime reductions in the 1990s. *Journal of Substance Abuse Treatment*, *16*(4), 329-335.
- Schut, J., Steer, R. A., & Gonzalez, F. I. (1975). Types of arrests recorded for methadone maintenance patients before, during, and after treatment. *British Journal of Addiction to Alcohol & Other Drugs*, *70*(1), 89-93.

Schwartz, R. P., Jaffe, J. H., Highfield, D. A., Callaman, J. M., & O'Grady, K. E. (2007). A randomized controlled trial of interim methadone maintenance: 10-Month follow-up. *Drug & Alcohol Dependence*, 86(1), 30-36.

Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000). Methadone Maintenance vs 180-Day Psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial. *JAMA*, 283(10), 1303-1310.

Sheerin, I., Green, T., Sellman, D., Adamson, S., & Deering, D. (2004). Reduction in crime by drug users on a methadone maintenance therapy programme in New Zealand. *New Zealand Medical Journal*, 117(1190), U795.

Simpson, D. D., Joe, G. W., & Rowan-Szal, G. A. (1997). Drug abuse treatment retention and process effects on follow-up outcomes. *Drug & Alcohol Dependence*, 47(3), 227-235.

Strang, J., Marsden, J., Cummins, M., Farrell, M., Finch, E., Gossop, M., Stewart, D., & Welch, S. (2000). Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. *Addiction*, 95(11), 1631-1645.

Teesson, M., Ross, J., Darke, S., Lynskey, M., Ali, R., Ritter, A. & Cooke, R. (2006). One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). *Drug and Alcohol Dependence*, 83(2), 174-180.

Walger, P., Baumgart, P., Wilke, G., Kupfer, U., von Eiff, M., & Dorst, K. G. (1989). Medizinische und psychosoziale Effekte der Methadon-Substitution HIV-infizierter Drogenabhängiger. *Psychotherapie, Psychosomatik, Medizinische Psychologie*, 39(11), 381-389.

Yancovitz, S., Des Jarlais, D., Peskoe Peyser, N., Drew, E., Friedman, P., Trigg, H., & Robinson, J. (1991). A randomised trial of an interim methadone maintenance clinic. *American Journal of Public Health*, 81, 1185-1191.

## 11 Appendix: Tables of General Study Descriptors

Table A1 : General description of studies included in the meta-analysis where the treatment group receives Heroin

| First author | Year | Outcome                               | Measure  | n <sub>exp</sub> | n <sub>control</sub> | Outcome <sub>exp</sub>  | Outcome <sub>control</sub> | Duration  | Treatment experimental | Treatment control                |
|--------------|------|---------------------------------------|--|------------------|----------------------|-------------------------|----------------------------|-----------|------------------------|----------------------------------|
| Dijkgraaf    | 2005 | arrests / property crime <sup>1</sup> | Self-report  | 193 <sup>2</sup> | 237 <sup>2</sup>     | 37(134)                 | 65(207)                    | 12 months | Methadone + Heroin     | <b>Methadone</b>                 |
| Perneger     | 1998 | Charged/any offense                   | Self-report  | 27               | 24 <sup>3</sup>      | 20/5 <sup>4</sup>       | 7/12 <sup>4</sup>          | 196 days  | Heroin                 | <b>Standard (many methadone)</b> |
| Hartnoll     | 1980 | Arrest/any offense                    | Self-report (checked against official records if possible) | 42               | 46                   | 52%                     | 72%                        | 12 months | Heroin                 | <b>Methadone</b>                 |
| March        | 2006 | Commission / any offense              | Nb days involved in criminal activity ; Self-report        | 31(27)           | 31(23)               | 12(13.7) <sup>5</sup>   | 3.8(7.6) <sup>5</sup>      | 9 months  | Methadone + Heroin     | <b>Methadone</b>                 |
| Löbmann      | 2008 | Charged / theft                       | Official data  | 419              | 406                  | 12.4%/9.5% <sup>2</sup> | 13.3%/12.4% <sup>6</sup>   | 12 months | Heroin                 | <b>Methadone</b>                 |

<sup>1</sup> mean (sd) for 100 participants

<sup>2</sup> initial numbers; 135 (70%, experimental) and 204 (86%, control) patients completed 12 months of treatment

<sup>3</sup> In the control group, only data for 21 participants is available and has been used.

<sup>4</sup> In the 6 months before the trial/after 196 days of trial (mean)

<sup>5</sup> diminution of mean number of days of crime with respect to t0

<sup>6</sup> In the month before beginning treatment/after 12 months of treatment

Table A2: General description of studies included in the meta-analysis where the treatment group receives Buprenorphine

| First author | Year | Outcome                     | Measure                             | n <sub>exp</sub> | n <sub>control</sub> | Outcome <sub>exp</sub>  | Outcome <sub>control</sub> | Duration              | Treatment experimental | Treatment control |
|--------------|------|-----------------------------|-------------------------------------|------------------|----------------------|-------------------------|----------------------------|-----------------------|------------------------|-------------------|
| Harris       | 2005 | Cost of crime / any offense | Self-report (and cost attributions) | 73               | 66                   | 6265(2028)              | 13223(10209)               | 12 months             | Buprenorphine          | Methadone         |
| Krook        | 2002 | Commission / any offense    | Self-report                         | 51               | 48                   | 96.1% <sup>1</sup>      | 99%% <sup>1</sup>          | 3 months              | Buprenorphine          | Placebo           |
| Magura       | 2008 | Arrest / any offense        | Self-report                         | 43               | 38                   | 0.69(0.95) <sup>2</sup> | 0.71(0.77) <sup>2</sup>    | 3 months post-release | Buprenorphine          | Methadone         |

<sup>1</sup> The numbers given in the research are « no criminal activities » (3.9% and 1.0%

<sup>2</sup> mean number of arrests(sd)

Table A3: General description of studies included in the meta-analysis where the treatment group receives Methadone

| First author | Year | Outcome                      | Measure   | n <sub>exp</sub> | n <sub>control</sub> | Outcome <sub>exp</sub>          | Outcome <sub>control</sub> | Duration    | Treatment experimental  | Treatment control          |
|--------------|------|------------------------------|---|------------------|----------------------|---------------------------------|----------------------------|-------------|-------------------------|----------------------------|
| Daley        | 2000 | Cost of crime / any offence  | Self-report (& cost estimates)                      | 54               | 183                  | 1584.99 (15321.54) <sup>1</sup> | -                          | 202 days    | Methadone               | Detoxification             |
| Teesson      | 2006 | Commission / any offence     | Self-report   | 227              | 141                  | 45%/19%                         | 61%/27%                    | 12 months   | Methadone               | Residential rehabilitation |
| Haglund      | 1978 | Arrest / any offence         | Self-report corroborated by official police records | 130              | 62                   | 39.2%/20.8%                     | 35.5%/                     | 24 months   | Methadone               | Detoxification             |
| Kinlock      | 2008 | Incarceration / any offence  | Self-report   | 68               | 63                   | 13%                             | 29%                        | 6 months    | Counselling + methadone | Counselling                |
| Dole         | 1969 | Incarceration / any offence  | Official sources                                    | 12               | 16                   | 25%                             | 93.8%                      | 7-10 months | Methadone               | Waiting list               |
| Bale         | 1980 | Arrest / any offence         | Self-report   | 59               | 150                  | 49.2%                           | 46%                        | 12 months   | Methadone               | Treatment community        |
| Newman       | 1979 | Conviction / any offence     | Unknown   | 50               | 50                   | 1.4 <sup>2</sup>                | 3.2 <sup>2</sup>           | 36 months   | Methadone               | Placebo                    |
| Schwartz     | 2007 | Illegal income / any offence | Self-report   | 199              | 120                  | 416 <sup>3</sup>                | 336 <sup>3</sup>           | 2-10 months | Methadone               | Waiting list               |
| Yankowitz    | 1991 | Incarceration / any offence  | Known status at end of study                        | 149              | 152                  | 1.4%                            | 0.7%                       | 16 months   | Methadone               | Waiting list               |
| Sees         | 2000 | ASI legal / any offence      | Self-report   | 77               | 57                   | 0.05(0.13) <sup>4</sup>         | 0.13(0.193) <sup>4</sup>   | 12 months   | Methadone               | Detoxification             |

<sup>1</sup>Regression coefficient

<sup>2</sup>Conviction rate per 100 man-months of enrolment

<sup>3</sup>Pre-post difference of illegal income

<sup>4</sup>mean(sd)

Table A4: General description of studies included in the meta-analysis where the treatment group receives Naltrexone

| First author | Year | Outcome   | Measure                            | n <sub>exp</sub> | n <sub>control</sub> | Outcome <sub>exp</sub> | Outcome <sub>control</sub> | Duration  | Treatment experimental         | Treatment control |
|--------------|------|---|------------------------------------|------------------|----------------------|------------------------|----------------------------|-----------|--------------------------------|-------------------|
| Cornish      | 1997 | Incarceration / any offense (+ probation violation) | Return to prison (official source) | 34               | 17                   | 26%                    | 56%                        | 6 months  | Counselling & Naltrexone       | Counselling       |
| Rawson       | 1979 | Incarceration / any offense                         | Official source                    | 20               | 15                   | 20%                    | 40%                        | 12 months | Behaviour therapy & Naltrexone | Behaviour therapy |